daclatasvir
Europe approves BMS hep C drug for HIV and liver transplant patients
February 1, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, daclatasvir, daklinza
The European Commission has approved the expanded use of Bristol Myers-Squibb’s hepatitis C drug Daklinza (daclatasvir), to include liver transplant …
BMS and Medicines Patent Pool collaborate to increase Hep C medicine access
November 25, 2015Manufacturing and Production, Research and Development Bristol-Myers Squibb, Medicines Patent Pool, daclatasvir, daklinza, hepatitis C
The Medicines Patent Pool (MPP) has announced its first licence for a hepatitis C medicine, signing an agreement with Bristol-Myers …
Conference round-up: companies go big on hepatitis C at EASL
April 29, 2015Sales and Marketing Bristol-Myers Squibb, EASL, Merck, daclatasvir, daklinza
Big pharma names posted favourable results for hepatitis C treatments as they jostled for position as market leaders at the …
BMS pulls hep C combo treatment in US
October 7, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Combo, HCV, asunaprevir, daclatasvir, hep C, sovaldi
Bristol-Myers Squibb will not attempt to bring its new combination hepatitis C treatment to the US market given the current …
CHMP approves six drugs including daclatasvir
June 30, 2014Sales and Marketing BMS, CHMP, HCV, Plavix, daclatasvir, daklinza, ge
A key advisory committee for the European Medicines Agency has given its approval to six new drugs at its latest …
Merck gets hep C boost as competition ramps up
April 11, 2014Research and Development, Sales and Marketing Merck, daclatasvir, hep C, sovaldi
Merck has released promising data from a trial which uses two of its investigational compounds to treat patients with hepatitis …
EMA to review daclatasvir
January 9, 2014Sales and Marketing BMS, EMA, daclatasvir, hep C
European regulators are to conduct a speedy investigation into one of Bristol-Myers Squibb’s investigational drugs for chronic hepatitis C virus …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
